Education And Debate

ABC of Breast Diseases: Metastatic breast cancer

BMJ 1994; 309 doi: https://doi.org/10.1136/bmj.309.6967.1501 (Published 03 December 1994) Cite this as: BMJ 1994;309:1501
  1. R C F Leonard,
  2. A Rodger,
  3. J M Dixon

    Few other cancers when they metastasise have such a variable natural course and effect on survival as breast cancer. Patients with hormone sensitive cancers may live for several years without any intervention other than various sequential hormonal manipulations. In contrast, patients with disease that is not hormone sensitive have a much shorter interval free of disease and shorter survival, reflecting the more aggressive biology of hormone independent cancers. The average period of survival after diagnosis of metastatic disease is 18-24 months, but this varies widely between patients.

    Clinical patterns of relapse predict future behaviour. Patients with a long interval without disease (more than two years) after primary diagnosis and favourable sites of recurrence (such as local lymph nodes and chest wall) survive longer than patients with either a short interval without disease or recurrence at other sites. Patients with visceral disease have the poorest outlook; these patients tend to have a short interval without disease and have cancers that are biologically more aggressive.

    FIG

    Median time of survival associated with sites of metastasis in patients with breast cancer.

    Treatment of metastatic disease

    Hormonal treatment of metastatic breast cancer

    Premenopausal women

    • Oophorectomy

    • Radiation menopause

    • Gonadotrophin releasing hormone analogues

    • Other treatments as for postmenopausal women

    Postmenopausal women

    • Tamoxifen (or pure antioestrogen when available)

    • Aromatase inhibitors (such as aminoglutethimide and 4-hydroxyandrostenedione

    • New oral aromatase inhibitors (currently in clinical trials)

    • Progestogens (such as medroxyprogesterone acetate and megestrol acetate)

    Antioestrogens, aromatase inhibitors, and progestogens may be used in virtually any sequence in responsive patients.

    A patient may present with metastatic breast carcinoma or develop a systemic recurrence after treatment for an apparently localised breast cancer. The aim of treatment is to produce effective control of symptoms with minimal side effects. In terms of drug treatment this ideal is only achieved by hormonal treatment in the 30% of patients whose cancers respond to such drugs. There is …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe